Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06793917
What this trial is testing

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
Fujian Cancer Hospital 269
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515625
What this trial is testing

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer (GC)AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Fudan University 46
Testing effectiveness (Phase 2)UnknownNCT04631757
What this trial is testing

Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 33
Early research (Phase 1)Study completedNCT04805307
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Who this might be right for
Advanced Solid TumorGastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)Pancreatic Cancer
Keymed Biosciences Co.Ltd 176
Testing effectiveness (Phase 2)Active Not RecruitingNCT04152499
What this trial is testing

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Who this might be right for
Epithelial Ovarian CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+7 more
Klus Pharma Inc. 1,410
Testing effectiveness (Phase 2)Study completedNCT03008278
What this trial is testing

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Who this might be right for
Metastatic Esophageal CarcinomaMetastatic Gastric CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+10 more
National Cancer Institute (NCI) 51
Early research (Phase 1)Ended earlyNCT02283359
What this trial is testing

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Who this might be right for
Esophageal CancerGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 3
Post-approval studies (Phase 4)Not Yet RecruitingNCT07502027
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Huazhong University of Science and Technology 55
Large-scale testing (Phase 3)Looking for participantsNCT07385703
What this trial is testing

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. 752
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)UnknownNCT05528367
What this trial is testing

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Locally Advanced Gastric Cancer
Zhejiang Cancer Hospital 33
Not applicableNot Yet RecruitingNCT07780968
What this trial is testing

Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

Who this might be right for
Esophageal CancerGastroEsophageal CancerGastroesophageal-junction Cancer+2 more
Jazz Pharmaceuticals 300
Large-scale testing (Phase 3)Study completedNCT02625610
What this trial is testing

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Who this might be right for
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
EMD Serono Research & Development Institute, Inc. 499
Testing effectiveness (Phase 2)Study completedNCT00515411
What this trial is testing

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastroesophageal Junction AdenocarcinomaGastric Cancer
Memorial Sloan Kettering Cancer Center 111
Large-scale testing (Phase 3)Not Yet RecruitingNCT07716449
What this trial is testing

QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 560
Testing effectiveness (Phase 2)Looking for participantsNCT05702229
What this trial is testing

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
AstraZeneca 163
Testing effectiveness (Phase 2)Looking for participantsNCT04660760
What this trial is testing

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+28 more
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Looking for participantsNCT06587425
What this trial is testing

The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT07327229
What this trial is testing

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited 132
Large-scale testing (Phase 3)Ended earlyNCT04675983
What this trial is testing

Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Who this might be right for
Gastric Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 36
Next Page
507
116